Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Apremilast Boosts Topical Therapy for Psoriasis

Adding apremilast to topical therapy in subjects with moderate plaque-type psoriasis produced a statistically significant improvement in disease outcome, a new study found. The open-label, 16-week study of apremilast in combination with topical steroids included a 4-week follow up off-treatment. 20 qualified participants were enrolled. The primary efficacy measure was mean change and mean percent change in product of BSA (%) x sPGA at week 16 compared to baseline. Assessments were made at baseline and weeks 4, 8, 16, and 20. Researchers found:

  • There was a statistically significant improvement in the mean change and mean percent change from baseline in product of sPGA x BSA at week 16, compared to baseline.
  • By week 16, there was a 36% improvement in median BSA from baseline.
  • The proportion of participants achieving PASI-50 at weeks 8 and 16 was 15% and 40%, respectively.
  • Participant quality of life was statistically improved from baseline at weeks 8 and 16.
  • A total of 34 adverse events were reported in 17 participants.


Aljaser M, Amar L, Kircik LH, Use of apremilast in patients who are dissatisfied with stable maintenance topical therapy. J Drugs Dermatol. 2019;18(4):336-340.